Key result
Positive inotropes remain a main therapeutic strategy for systolic heart failure despite safety concerns, but should be used for short durations at low doses and stopped as early as possible.
Why the study?
Does the use of positive inotropes improve outcomes in patients with systolic heart failure?
Does the use of positive inotropes improve outcomes in patients with systolic heart failure?
This review summarizes clinical trials and guidelines regarding the use of positive inotropes in systolic heart failure, emphasizing short duration and low dose due to safety concerns.
No takes yet. Share an insight, caveat, or question.
Supports short-term low-dose positive inotrope use in systolic HF; leaves open need for RCTs on long-term safety.
Amin et al. (2012) conducted a review in Systolic heart failure. Positive inotropes was evaluated. Positive inotropes remain a main therapeutic strategy for systolic heart failure despite safety concerns, but should be used for short durations at low doses and stopped as early as possible.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: